US$ 26.52
glp-1 nutritionist Nutritional priorities to support therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society How Are GLP-1 Drugs Affecting
Description
ZP 6590 [64] ZP-6590 is a GIPR agonist, and has been designed to both reduce nausea and food intake

There are some studies using lactisole, a sweet taste receptor antagonist, that have shown reduced GLP-1 and PYY secretion in response to glucose, but no effect on CCK release (6870)

doi: 10.1152/jappl.2001.91.3.1421
Please note: These products are not medicines and do not replace medical treatment

Off-Label Use: Critical Considerations Using GLP-1RAs for psychiatric conditions is considered off-label use

Diabetes, pregnancy and breast-feeding | Treatment summaries | BNF NICE
